# Neumora Therapeutics, Inc. (NMRA)

> Source: Nexqual · https://nexqual.com/NMRA · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Neumora Therapeutics, Inc. (NMRA), nexqual.com/NMRA" · informational, not investment advice.

**Price:** USD 0.43 (+20.45% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.35 · day 0.36–0.46 · 52w 0.32–3.65 · market cap $80.2M · NMS

## Key facts
- Analysts: Buy (mean 2.22 on a 1–5 scale) (9 analysts), mean target USD 6.14 (range 3–14).
- Total return with dividends: 1Y -76.0% vs S&P 500 +18.1%; 5Y -97.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.19, revenue estimate $0K.

## Analysts
Consensus Buy (mean 2.22 on a 1–5 scale), 9 analysts; mean target USD 6.14 (low 3, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | RBC Capital | Target lowered | Outperform | $7 → $5 |
| 2026-06-18 | Mizuho | Target lowered | Outperform | $6 → $4 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2023-09-11) |
|---|---|---|
| Total return | -76.0% | -97.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -76.1% | -69.1% |
| Volatility (annualized) | 128.2% | 135.6% |
| Max drawdown | -90.1% (Feb 2026→Oct 2026) | -97.8% (Feb 2024→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/NMRA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt